Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis
- 1 July 2003
- journal article
- website
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (7) , 861-865
Abstract
Study Objectives. To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end‐stage renal disease who require hemodialysis.Design. Retrospective chart review.Setting. Ambulatory hemodialysis clinic.Patients. Forty ambulatory patients receiving hemodialysis.Measurements and Main Results. Of the 40 patients (26 men, 14 women, mean ± SD age 64.8 ± 11.5 yrs), diabetes mellitus was the cause of end‐stage renal disease in 37 (92.5%). The men were older than the women (mean ± SD age 67.65 ± 11.43 yrs and 59.58 ± 10.6 yrs, respectively, p=0.03). Additional demographic data collected were start date and cause of end‐stage renal disease, comorbid conditions, drug profile, hospitalization dates, and reason for admission. Laboratory values were obtained for hematocrit, iron indexes (transferrin saturation and ferritin), mean corpuscular volume, and hemoglobin A1c (A1C); body weight before and after dialysis, and predialysis systolic and diastolic blood pressures were measured. All monitoring parameters were evaluated for 3 months before and after the start of therapy. Three patients were hospitalized for new or worsening chronic heart failure (two were receiving rosiglitazone therapy, one pioglitazone, p=0.555). Changes in A1C values were reviewed to determine thiazolidinedione efficacy; no statistical difference was observed between thiazolidinedione agents prescribed. Combined thiazolidinedione data yielded nonsignificant effects for all clinical and laboratory findings except A1C (‐0.61%, p=0.05) and blood pressure (systolic −5.57 ± 12.09 mm Hg, p=0.01; diastolic −3.24 ± 6.17 mm Hg, p=0.002).Conclusion. Thiazolidinedione therapy is safe and effective for ambulatory patients receiving hemodialysis. However, as we found that these drugs reduced systolic and diastolic blood pressure, further investigation into this drug effect is warranted.Keywords
This publication has 16 references indexed in Scilit:
- Drug Record Discrepancies in an Outpatient Electronic Medical Record: Frequency, Type, and Potential Impact on Patient Care at a Hemodialysis CenterPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Factors associated with medication-related problems in ambulatory hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive PatientsDiabetes Care, 2003
- Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal DiseaseJournal of the American Society of Nephrology, 2002
- Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: Effects on the very-low-density and high-density lipoprotein particle distributionMetabolism, 2002
- Glycemic Control Is a Predictor of Survival for Diabetic Patients on HemodialysisDiabetes Care, 2001
- Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2001
- Rosiglitazone Monotherapy Is Effective in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2001
- IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000American Journal of Kidney Diseases, 2001
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000